Among them, bortezomib (BTZ; brand name: Velcade) was the first-in-class proteasome inhibitor for the treatment of MM, and it can dramatically induce MM cell death by stabilizing IκBα protein to inhibit the activation of NF-κB signaling pathway (Yao et al., 2018). This evidence concerns the gene NFKB1 and Miyoshi myopathy.